Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;47:545-551
Published online before print December 19, 2005, doi: 10.1161/01.HYP.0000197033.54756.83
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/3/545    most recent
01.HYP.0000197033.54756.83v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dubinion, J. H.
Right arrow Articles by Jackson, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dubinion, J. H.
Right arrow Articles by Jackson, E. K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Hypertension - basic studies
Right arrow Receptor pharmacology

(Hypertension. 2006;47:545.)
© 2006 American Heart Association, Inc.


Part 2 Original Articles

Pancreatic Polypeptide-Fold Peptide Receptors and Angiotensin II–Induced Renal Vasoconstriction

John H. Dubinion; Zaichuan Mi; Chongxue Zhu; Liping Gao; Edwin K. Jackson

From the Center for Clinical Pharmacology, Departments of Medicine (Z.M., C.Z., L.G., E.K.J.) and Pharmacology (J.H.D., E.K.J.), University of Pittsburgh School of Medicine, Pittsburgh, Pa.

Correspondence to Edwin K. Jackson, Center for Clinical Pharmacology, University of Pittsburgh School of Medicine, 100 Technology Dr, Suite 450, Pittsburgh, PA 15219. E-mail edj{at}pitt.edu

The Gi pathway augments renal vasoconstriction induced by angiotensin II in spontaneously hypertensive but not normotensive Wistar-Kyoto rats. Because the Gi-coupled pancreatic polypeptide (PP)-fold peptide receptors Y1 and Y2 are expressed in kidneys and are activated by endogenous PP-fold peptides, we tested the hypothesis that these receptors regulate angiotensin II-induced renal vasoconstriction in kidneys from hypertensive but not normotensive rats. A selective Y1-receptor agonist [(Leu31,Pro34)-neuropeptide Y; 6 to 10 nmol/L] greatly potentiated angiotensin II–induced changes in perfusion pressure in isolated, perfused kidneys from hypertensive but not normotensive rats. A selective Y2-receptor agonist (peptide YY3-36; 6 nM) only slightly potentiated angiotensin II–induced renal vasoconstriction and only in kidneys from hypertensive rats. Neither the Y1-receptor nor the Y2-receptor agonist increased basal perfusion pressure. BIBP3226 (1 µmol/L, highly selective Y1-receptor antagonist) and BIIE0246 (1 µmol/L, highly selective Y2-receptor antagonist) completely abolished potentiation by (Leu31,Pro34)-neuropeptide Y and peptide YY3-36, respectively. Y1-receptor and Y2-receptor mRNA and protein levels were expressed in renal microvessels and whole kidneys, but the abundance was similar in kidneys from hypertensive and normotensive rats. Both Y1-receptor–induced and Y2-receptor–induced potentiation of angiotensin II–mediated renal vasoconstriction was completely abolished by pretreatment with pertussis toxin (30 µg/kg IV, blocks Gi proteins). These data indicate that, in kidneys from genetically hypertensive but not normotensive rats, Y1-receptor activation markedly enhances angiotensin II–mediated renal vasoconstriction by a mechanism involving Gi. Although Y2 receptors can also potentiate angiotensin II–mediated renal vasoconstriction via Gi, the effect is modest compared with Y1 receptors. These findings may have important implications for the etiology of genetic hypertension.


Key Words: receptors • neuropeptides • peptides • hypertension




This article has been cited by other articles:


Home page
HypertensionHome page
E. K. Jackson and Z. Mi
Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension
Hypertension, June 1, 2008; 51(6): 1637 - 1642.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, M. Zhang, W. Liu, and Z. Mi
Inhibition of Renal Dipeptidyl Peptidase IV Enhances Peptide YY1 36-Induced Potentiation of Angiotensin II-Mediated Renal Vasoconstriction in Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 431 - 437.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. H. Dubinion, Z. Mi, and E. K. Jackson
Role of Renal Sympathetic Nerves in Regulating Renovascular Responses to Angiotensin II in Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1330 - 1336.
[Abstract] [Full Text] [PDF]